Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
OBJECTIVE
The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine.


METHODS
The body mass index of male schizophrenic adolescent inpatients treated with olanzapine (N=10) and of 10 matched patients treated with haloperidol (N=10) were measured at baseline and after 4 weeks of treatment. For the patients treated with olanzapine, caloric intake, resting energy expenditure, and physical activity (determined through accelerometry and heart rate monitoring) were assessed at baseline and after 4 weeks of treatment.


RESULTS
Body mass index significantly increased in those treated with olanzapine but not in those given haloperidol. The increase in body mass index was due to an increase in caloric intake without change in diet composition. Olanzapine had no significant effect on resting energy expenditure. Daily energy expenditure was very low before and after treatment.


CONCLUSIONS
Olanzapine-induced weight gain is associated with a general increase in caloric intake.
Gothelf
Doron
D
Behavioral Genetic Clinic, Richard E. Feinberg Department of Psychiatry, Schneider Children's Medical Center of Israel, Petah Tiqwa. gothelf@post.tau.ac.il
Falk
Bareket
B
Singer
Pierre
P
Kairi
Michal
M
Phillip
Moshe
M
Zigel
Levana
L
Poraz
Irit
I
Frishman
Siegal
S
Constantini
Naama
N
Zalsman
Gil
G
Weizman
Abraham
A
Apter
Alan
A
D000293:Adolescent; D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015992:Body Mass Index; D004435:Eating / Q000187:drug effects*; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced*; D000077152:Olanzapine; D005082:Physical Exertion / Q000187:drug effects / Q000502:physiology; D010865:Pilot Projects; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D006220:Haloperidol; D000077152:Olanzapine